Steroids in Occipital Nerve Block for Treatment of Headache

Status Recruiting

Clinical Trial Summary

Currently there is limited evidence of benefit for the addition of steroids to occipital nerve blocks for treatment of headache, and not all steroids have been explored. The purpose of this research is to learn more about whether the addition of a specific kind of steroid (dexamethasone) provides any additional benefit to nerve blocks.

Clinical Trial Description

Patients who are referred by their neurology provider for occipital nerve block as treatment of headache according to current accepted standard of care will be considered for this study. Baseline data will be obtained from the patients prior to proceeding with their nerve block and their headache diagnosis will be recorded based on electronic medical record review. Patients will be randomized to one of two treatment arms, anesthetic with dexamethasone or anesthetic without dexamethasone. The injectate will be the same color and amount of solution for each trial arm. Thus, the neurology provider performing the injection remains blinded and the patient remains blinded. Injection sites will be inspected to ensure no active bleeding, infection, cranial bone or cervical spine defects/prior surgeries that prohibit safe use of landmark-based technique. A neurologist who is experienced at performing nerve blocks will administer the injections to the bilateral greater and lesser occipital nerves using the landmark-based technique. The occipital protuberance and mastoid process are palpated, with the location of the greater occipital nerve at approximately 1/3 the distance laterally and the lesser occipital nerve at approximately 2/3 the distance laterally along the nuchal ridge for a total of 4 injection sites. Patients will be observed for approximately 10 minutes after the procedure to monitor for any immediate adverse effects and to ensure that anesthesia in the distribution of the injected nerves was achieved. Then, they will be instructed to keep a headache diary after treatment and will be provided a written example diary. A study staff who remains blinded to the patient's trial arm (but not necessarily the neurology provider who performed the injection) will contact the patients via telephone at 1, 2 and 4 weeks to assess response to treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05732532
Study type	Interventional
Source	Mayo Clinic
Contact
Status	Recruiting
Phase	Phase 4
Start date	February 17, 2023
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03472872` - A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache	Phase 4
Withdrawn	`NCT05410366` - Safe Harbors in Emergency Medicine, Specific Aim 3
Withdrawn	`NCT02866084` - Neuromodulation Treatment of Vestibular Migraines	N/A
Active, not recruiting	`NCT03537573` - Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care	N/A
Recruiting	`NCT05891808` - miR-155 Expression in Episodic and Chronic Migraine
Not yet recruiting	`NCT04352218` - Safety Profile of PETALO CVS in the Treatment of Non-thrombotic Internal Jugular Vein Stenosis and Chronic Headache	Phase 2
Completed	`NCT02734992` - Acceptance and Commitment Therapy vs Medical Treatment as Usual Wait-list Control for Primary Headache Sufferers	N/A
Completed	`NCT01153789` - Study of Oculomotor Dysfunction Leading to Children Vertigo	N/A
Completed	`NCT01327118` - Prostaglandin F2alpha in a Human Headache Model	N/A
Not yet recruiting	`NCT00969995` - Identification of Inflammatory Markers in Migraine Patients	N/A
Not yet recruiting	`NCT00752921` - Randomized Placebo Controlled Trial With Etoricoxib That is Taken to Prevent the Yom Kippur Headache	Phase 4
Completed	`NCT00212810` - Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache.	Phase 4
Terminated	`NCT00291395` - PGI2 Induced Headache and Cerebral Haemodynamics in Healthy Volunteers	Phase 1
Completed	`NCT00263094` - An End to the Yom Kippur (and Ramadan) Headache	N/A
Completed	`NCT00135122` - Prednisolone in the Treatment of Withdrawal Headache in Probable Medication Overuse Headache	Phase 3
Completed	`NCT02475005` - An Intervention to Improve Adolescent Headache Self-management	N/A
Completed	`NCT03163901` - The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury	N/A
Completed	`NCT01664585` - Exercise Training With Physically Active Lifestyle to Reduce Headache and Quality of Life	N/A
Completed	`NCT04632420` - Evaluation of Headache and Childbirth in a Chronic Pain Population
Recruiting	`NCT05033613` - Home Blood Pressure Monitoring Before and After COVID-19 Vaccination in Patients at High Risk of Cardiovascular Disease

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.